<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE Summary >
<Summary id="CDR0000062931" LegacyPDQID=""><SummaryMetaData><SummaryType>Treatment</SummaryType><SummaryAudience>Health professionals</SummaryAudience><SummaryLanguage>English</SummaryLanguage><SummaryDescription>Expert-reviewed information summary about the treatment of paranasal sinus and nasal cavity cancer.</SummaryDescription><SummaryURL xref="http://cancer.gov/types/head-and-neck/hp/paranasal-sinus-treatment-pdq">Paranasal Sinus and Nasal Cavity Cancer (PDQ®): Treatment</SummaryURL><MainTopics><TermRef ref="CDR0000040127">paranasal sinus and nasal cavity cancer</TermRef></MainTopics></SummaryMetaData><SummaryTitle>Paranasal Sinus and Nasal Cavity Cancer Treatment (PDQ®)</SummaryTitle><AltTitle TitleType="Navlabel">Paranasal Sinus &amp; Nasal Cavity Cancer Treatment</AltTitle><AltTitle TitleType="Short">Paranasal Sinus and Nasal Cavity Cancer Treatment</AltTitle><SummarySection id="_1"><SectMetaData><SpecificDiagnosis ref="CDR0000040127">paranasal sinus and nasal cavity cancer</SpecificDiagnosis><SectionType>Prognosis--legacy</SectionType></SectMetaData><Title>General Information About Paranasal Sinus and Nasal Cavity Cancer</Title><SummarySection id="_308"><Title>Incidence and Mortality</Title><Para id="_2">The majority of tumors of the paranasal sinuses present with advanced disease,
and cure rates are generally poor (≤50%).  Squamous cell carcinoma (SCC) is the most frequent
type of malignant tumor in the nose and paranasal sinuses (70%–80%). 
Papillomas are distinct entities that may undergo malignant degeneration.  The
cancers grow within the bony confines of the sinuses and are often asymptomatic
until they erode and invade adjacent structures.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/>
</Para><Para id="_314">Nodal involvement is
infrequent.  Although metastases from both  the nasal cavity and paranasal sinuses may occur, and distant metastases are found in 20% to 40% of
patients who do not respond to treatment, locoregional recurrence accounts for the majority of cancer deaths since most patients die of direct extension into vital areas of the skull or of
rapidly recurring local disease.</Para><Para id="_315">Cancers of the maxillary sinus are the most common of the paranasal sinus
cancers.  Tumors of the ethmoid sinuses, nasal vestibule, and nasal cavity are
less common, and tumors of the sphenoid and frontal sinuses are rare.
</Para></SummarySection><SummarySection id="_316"><Title>Anatomy</Title><Para id="_317">The major lymphatic drainage route of the maxillary antrum is through the
lateral and inferior collecting trunks to the first station submandibular,
parotid, and jugulodigastric nodes and through the superoposterior trunk to
retropharyngeal and jugular nodes.
</Para></SummarySection><SummarySection id="_309"><Title>Clinical Evaluation and Follow-up</Title><Para id="_3">Pretreatment evaluation and staging, as well as the need for
multidisciplinary planning of treatment, is very important.  Generally, the
first opportunity to treat patients with head and neck cancers is the most
effective, though occasionally salvage surgery or salvage radiation therapy,
as appropriate, may be successful.  Since most treatment failures occur
within 2 years, the follow-up of patients must be frequent and meticulous
during this period.  In addition, because nearly 33% of these patients
develop second primary cancers in the aerodigestive tract, a lifetime of
follow-up is essential.</Para></SummarySection><SummarySection id="_311"><Title>Carcinogenesis and Risk Factors</Title><Para id="_6">Some data indicate that various industrial exposures may be related to cancer
of the paranasal sinus and nasal cavity.  The risk of a second primary head and
neck tumor is considerably increased.<Reference refidx="4"/> A subgroup has shown that paranasal sinus and nasal cavity SCC are associated with human papilloma  virus (HPV) infection and that HPV-positive patients   may have a better prognosis than those who are HPV-negative.<Reference refidx="5"/>
</Para></SummarySection><ReferenceSection><Citation idx="1">Mendenhall WM, Werning JW, Pfister DG: Treatment of head and neck cancer. In: DeVita VT Jr, Lawrence TS, Rosenberg SA: Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, Pa: Lippincott Williams &amp; Wilkins, 2011, pp 729-80.</Citation><Citation idx="2">Laramore GE, ed.: Radiation Therapy of Head and Neck Cancer. Berlin: Springer-Verlag, 1989.</Citation><Citation idx="3">Thawley SE, Panje WR, Batsakis JG, et al., eds.: Comprehensive Management of Head and Neck Tumors. 2nd ed. Philadelphia, Pa: WB Saunders, 1999.</Citation><Citation idx="4">Johns ME, Kaplan MJ: Advances in the management of paranasal sinus tumors. In: Wolf GT, ed.: Head and Neck Oncology. Boston, Mass: Martinus Nijhoff Publishers, 1984, pp 27-52.</Citation><Citation idx="5" PMID="19365846">Alos L, Moyano S, Nadal A, et al.: Human papillomaviruses are identified in a subgroup of sinonasal squamous cell carcinomas with favorable outcome. Cancer 115 (12): 2701-9, 2009.</Citation></ReferenceSection></SummarySection><SummarySection id="_7"><SectMetaData><SpecificDiagnosis ref="CDR0000040127">paranasal sinus and nasal cavity cancer</SpecificDiagnosis><SectionType>Cellular classification--legacy</SectionType></SectMetaData><Title>Cellular Classification of Paranasal Sinus and Nasal Cavity Cancer</Title><Para id="_8">The most common cell type for paranasal sinus and nasal cavity cancers is
squamous cell carcinoma.  Minor salivary gland tumors comprise 10% to 15% of
these neoplasms.  Malignant melanoma presents in &lt;1% of neoplasms in
this region.  Some 5% of cases are  malignant lymphomas.<Reference refidx="1"/><Reference refidx="2"/>
</Para><Para id="_9">Esthesioneuroepithelioma, sometimes confused with undifferentiated carcinoma or
undifferentiated lymphoma, arises from the olfactory nerves.<Reference refidx="3"/>
</Para><Para id="_10">Chondrosarcoma, osteosarcoma, Ewing sarcoma, and most soft tissue sarcomas
have been reported for this region.
</Para><Para id="_11">Inverting papilloma is considered a low-grade benign tumor with a tendency to
recur and, in a small percentage of cases, to transform into a malignant tumor.
</Para><Para id="_12">Midline granuloma, a progressively destructive condition, involves this region
as well.
</Para><ReferenceSection><Citation idx="1">Mendenhall WM, Werning JW, Pfister DG: Treatment of head and neck cancer. In: DeVita VT Jr, Lawrence TS, Rosenberg SA: Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, Pa: Lippincott Williams &amp; Wilkins, 2011, pp 729-80.</Citation><Citation idx="2" PMID="11338653" MedlineID="21237326">Goldenberg D, Golz A, Fradis M, et al.: Malignant tumors of the nose and paranasal sinuses: a retrospective review of 291 cases. Ear Nose Throat J 80 (4): 272-7, 2001.</Citation><Citation idx="3" PMID="17372086">Jethanamest D, Morris LG, Sikora AG, et al.: Esthesioneuroblastoma: a population-based analysis of survival and prognostic factors. Arch Otolaryngol Head Neck Surg 133 (3): 276-80, 2007.</Citation></ReferenceSection></SummarySection><SummarySection id="_13"><SectMetaData><SpecificDiagnosis ref="CDR0000040127">paranasal sinus and nasal cavity cancer</SpecificDiagnosis><SectionType>Stage explanation--legacy</SectionType></SectMetaData><Title>Stage Information for Paranasal Sinus and Nasal Cavity Cancer</Title><Para id="_14">The staging systems are clinical estimates of the extent of disease.  The
assessment of the tumor is based on inspection, palpation, and direct endoscopy
when necessary.  The tumor must be confirmed histologically, and any other
pathological data obtained on biopsy may be included.  The appropriate nodal
drainage areas are examined by careful palpation.  Computed tomographic and/or
magnetic resonance imaging studies are generally required to adequately
evaluate tumor extent prior to attempted surgical resection or definitive
radiation therapy.  If a patient relapses, complete restaging must be done to select the appropriate additional therapy.<Reference refidx="1"/><Reference refidx="2"/>
</Para><SummarySection id="_286"><Title>Definitions of TNM</Title><Para id="_283">Staging of nasal cavity and paranasal sinus carcinomas is not as well
established as for other head and neck tumors.  For cancer of the maxillary sinus, the nasal cavity,  and the ethmoid sinus, the
American Joint Committee on Cancer (AJCC) has designated staging by TNM classification.<Reference refidx="3"/></Para><Table id="_276"><Title>Table 1.  Primary Tumor (T)<Superscript>a</Superscript></Title><TGroup Cols="2"><ColSpec ColName="col1" ColNum="1" ColWidth="13.62%"/><ColSpec ColName="col2" ColNum="2" ColWidth="86.37%"/><TFoot><Row><entry NameEnd="col2" NameSt="col1"><Superscript>a</Superscript>Reprinted with permission from AJCC: Paranasal sinus and nasal cavity. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 69-78.</entry></Row></TFoot><TBody><Row><entry>TX</entry><entry>Primary tumor cannot be assessed.</entry></Row><Row><entry>T0</entry><entry>No evidence of primary tumor.</entry></Row><Row><entry>Tis</entry><entry>Carcinoma <Emphasis>in situ</Emphasis>.</entry></Row><Row><entry Align="Center" NameEnd="col2" NameSt="col1"><Emphasis>Maxillary Sinus</Emphasis></entry></Row><Row><entry>T1</entry><entry>Tumor limited to maxillary sinus mucosa with no erosion or destruction of bone.</entry></Row><Row><entry>T2</entry><entry>Tumor causing bone erosion or destruction including extension into the hard palate and/or middle nasal meatus, except extension to posterior wall of maxillary sinus and pterygoid plates.</entry></Row><Row><entry>T3</entry><entry>Tumor invades any of the following: bone of the posterior wall of maxillary sinus, subcutaneous tissues, floor or medial wall of orbit, pterygoid fossa, or ethmoid sinuses.</entry></Row><Row><entry MoreRows="1">T4a</entry><entry>Moderately advanced local disease.</entry></Row><Row><entry>Tumor invades anterior orbital contents, skin of cheek, pterygoid plates, infratemporal fossa, cribriform plate, or sphenoid or frontal sinuses.</entry></Row><Row><entry MoreRows="1">T4b</entry><entry>Very advanced local disease.</entry></Row><Row><entry>Tumor invades any of the following: orbital apex, dura, brain, middle cranial fossa, cranial nerves other than maxillary division of trigeminal nerve (V<Subscript>2</Subscript>), nasopharynx, or clivus.</entry></Row><Row><entry Align="Center" NameEnd="col2" NameSt="col1"><Emphasis>Nasal Cavity and Ethmoid Sinus</Emphasis></entry></Row><Row><entry>T1</entry><entry>Tumor restricted to any one subsite, with or without bony invasion.</entry></Row><Row><entry>T2</entry><entry>Tumor invading two subsites in a single region or extending to involve an adjacent region within the nasoethmoidal complex, with or without bony invasion.</entry></Row><Row><entry>T3</entry><entry>Tumor extends to invade the medial wall or floor of the orbit, maxillary sinus, palate, or cribriform plate.</entry></Row><Row><entry MoreRows="1">T4a</entry><entry>Moderately advanced local disease.</entry></Row><Row><entry>Tumor invades any of the following: anterior orbital contents, skin of nose or cheek, minimal extension to anterior cranial fossa, pterygoid plates, or sphenoid or frontal sinuses.</entry></Row><Row><entry MoreRows="1">T4b</entry><entry>Very advanced local disease.</entry></Row><Row><entry>Tumor invades any of the following: orbital apex, dura, brain, middle cranial fossa, cranial nerves other than (V<Subscript>2</Subscript>), nasopharynx, or clivus.</entry></Row></TBody></TGroup></Table><Table id="_277"><Title>Table 2.  Regional Lymph Nodes(N)<Superscript>a</Superscript></Title><TGroup Cols="2"><ColSpec ColName="col1" ColNum="1" ColWidth="13.71%"/><ColSpec ColName="col2" ColNum="2" ColWidth="86.28%"/><TFoot><Row><entry NameEnd="col2" NameSt="col1"><Superscript>a</Superscript>Reprinted with permission from AJCC: Paranasal sinus and nasal cavity. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 69-78.</entry></Row></TFoot><TBody><Row><entry>NX</entry><entry>Regional lymph nodes cannot be assessed.</entry></Row><Row><entry>N0</entry><entry>No regional lymph node metastasis.</entry></Row><Row><entry>N1</entry><entry>Metastasis in a single ipsilateral lymph node, ≤3 cm in greatest dimension.</entry></Row><Row><entry>N2</entry><entry>Metastasis in a single ipsilateral lymph node, &gt;3 cm but ≤6 cm in greatest dimension, or metastases in multiple ipsilateral lymph nodes, ≤6 cm in greatest dimension, or in bilateral or contralateral lymph nodes, ≤6 cm in greatest dimension.</entry></Row><Row><entry>N2a</entry><entry>Metastasis in a single ipsilateral lymph node, &gt;3 cm but ≤6 cm in greatest dimension.</entry></Row><Row><entry>N2b</entry><entry>Metastases in multiple ipsilateral lymph nodes, ≤6 cm in greatest dimension.</entry></Row><Row><entry>N2c</entry><entry>Metastases in bilateral or contralateral lymph nodes, ≤6 cm in greatest dimension.</entry></Row><Row><entry>N3</entry><entry>Metastasis in a lymph node, &gt;6 cm in greatest dimension.</entry></Row></TBody></TGroup></Table><Table id="_278"><Title>Table 3.  Distant Metastasis (M)<Superscript>a</Superscript></Title><TGroup Cols="2"><ColSpec ColName="col1" ColNum="1" ColWidth="50.00%"/><ColSpec ColName="col2" ColNum="2" ColWidth="50.00%"/><TFoot><Row><entry NameEnd="col2" NameSt="col1"><Superscript>a</Superscript>Reprinted with permission from AJCC: Paranasal sinus and nasal cavity. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 69-78.   </entry></Row></TFoot><TBody><Row><entry>M0</entry><entry>No distant metastasis.</entry></Row><Row><entry>M1</entry><entry>Distant metastasis.</entry></Row></TBody></TGroup></Table><Table id="_279"><Title>Table 4.  Anatomic Stage/Prognostic Groups<Superscript>a</Superscript></Title><TGroup Cols="4"><ColSpec ColName="col1" ColNum="1" ColWidth="25.00%"/><ColSpec ColName="col2" ColNum="2" ColWidth="25.00%"/><ColSpec ColName="col3" ColNum="3" ColWidth="25.00%"/><ColSpec ColName="col4" ColNum="4" ColWidth="25.00%"/><THead><Row><entry Align="Center">Stage</entry><entry Align="Center">T</entry><entry Align="Center">N</entry><entry Align="Center">M</entry></Row></THead><TFoot><Row><entry NameEnd="col4" NameSt="col1"><Superscript>a</Superscript>Reprinted with permission from AJCC: Paranasal sinus and nasal cavity. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 69-78.</entry></Row></TFoot><TBody><Row><entry>0</entry><entry>Tis</entry><entry>N0</entry><entry>M0</entry></Row><Row><entry> I</entry><entry>T1</entry><entry>N0</entry><entry>M0</entry></Row><Row><entry>II</entry><entry>T2</entry><entry>N0</entry><entry>M0</entry></Row><Row><entry MoreRows="3"> III</entry><entry>T3</entry><entry>N0</entry><entry>M0</entry></Row><Row><entry>T1</entry><entry>N1</entry><entry>M0</entry></Row><Row><entry>T2</entry><entry>N1</entry><entry>M0</entry></Row><Row><entry>T3</entry><entry>N1</entry><entry>M0</entry></Row><Row><entry MoreRows="5"> IVA</entry><entry>T4a</entry><entry>N0</entry><entry>M0</entry></Row><Row><entry>T4a</entry><entry>N1</entry><entry>M0</entry></Row><Row><entry>T1</entry><entry>N2</entry><entry>M0</entry></Row><Row><entry>T2</entry><entry>N2</entry><entry>M0</entry></Row><Row><entry>T3</entry><entry>N2</entry><entry>M0</entry></Row><Row><entry>T4a</entry><entry>N2</entry><entry>M0</entry></Row><Row><entry MoreRows="1">IVB</entry><entry>T4b</entry><entry>Any N</entry><entry>M0</entry></Row><Row><entry>Any T</entry><entry>N3</entry><entry>M0</entry></Row><Row><entry> IVC</entry><entry>Any T</entry><entry>Any N</entry><entry>M1</entry></Row></TBody></TGroup></Table></SummarySection><ReferenceSection><Citation idx="1">Mendenhall WM, Werning JW, Pfister DG: Treatment of head and neck cancer. In: DeVita VT Jr, Lawrence TS, Rosenberg SA: Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, Pa: Lippincott Williams &amp; Wilkins, 2011, pp 729-80.</Citation><Citation idx="2">Laramore GE, ed.: Radiation Therapy of Head and Neck Cancer. Berlin: Springer-Verlag, 1989.</Citation><Citation idx="3">Nasal cavity and paranasal sinuses. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 69-78.</Citation></ReferenceSection></SummarySection><SummarySection id="_54"><SectMetaData><SpecificDiagnosis ref="CDR0000040127">paranasal sinus and nasal cavity cancer</SpecificDiagnosis><SectionType>Treatment option overview--legacy</SectionType></SectMetaData><Title>Treatment Option Overview</Title><Para id="_55">Except for T1 mucosal carcinomas, the accepted method of treatment is a
combination of radiation therapy and surgery.  The incidence of lymph node
metastases is generally low (approximately 20% of all cases).  Thus, routine
radical neck dissection or elective neck radiation therapy is recommended only for
patients presenting with positive nodes.  
</Para><Para id="_210">For patients with operable tumors,
radical surgery is generally performed first to remove the bulk of the tumor
and to establish drainage of the affected sinus(es).  This is followed by
postoperative radiation therapy.  Some institutions continue to give a full
dose of radiation therapy preoperatively for all stage II and stage III tumors and
to operate 4 to 6 weeks later.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/>  A review of published clinical results of
radical radiation therapy for head and neck cancer suggests a significant loss
of local control when the administration of radiation therapy was prolonged;
therefore, lengthening of standard treatment schedules should be avoided
whenever possible.<Reference refidx="4"/></Para><SummarySection id="_211"><Title>Surgery</Title><Para id="_292">Surgical exploration may be required to determine operability.</Para><Para id="_212">  Destruction of
the base of skull (i.e., anterior cranial fossa), cavernous sinus, or the pterygoid
process; infiltration of the mucous membranes of the nasopharynx; or
nonresectable lymph node metastases are relative contraindications to surgery. 
Surgical approaches include fenestration with removal of the bulk tumor, which
is usually followed by radiation therapy or block resection of the upper jaw. 
A combined craniofacial approach, including resection of the floor of the
anterior cranial fossa is used with success in selected patients.<Reference refidx="5"/>  Removal of
the eye is performed if the orbit is extensively invaded by cancer.  Clinically
positive nodes, if resectable, may be treated with radical neck dissection.
</Para></SummarySection><SummarySection id="_213"><Title>Radiation Therapy</Title><Para id="_214">Radiation therapy must be carried to high doses for any significant probability
of permanent control.  The treatment volume must include all of the maxillary
antrum and involved hemiparanasal sinus and contiguous areas.  The orbit and
its contents are excluded except under unusual circumstances.  Lymph nodes of
the neck, when palpable, should be treated in conjunction with treatment of
advanced carcinomas of the antrum.  This may be unnecessary for early tumors.</Para><Para id="_215">Accumulating evidence has demonstrated a high incidence (&gt;30%–40%) of
hypothyroidism in patients who have received external-beam radiation therapy to the
entire thyroid gland or to the pituitary gland.  Thyroid function testing of
patients should be considered prior to therapy and as part of posttreatment
follow-up.<Reference refidx="6"/><Reference refidx="7"/></Para></SummarySection><SummarySection id="_216"><Title>Recurrent Disease</Title><Para id="_217">For patients with recurrent disease, chemotherapy trials should be considered. 
Chemotherapy for recurrent squamous cell cancer of the head and neck has been
shown to be efficacious as palliation and may improve quality of life and
length of survival.  Various drug combinations including cisplatin,
fluorouracil, and methotrexate are effective.<Reference refidx="8"/><Reference refidx="9"/></Para><Para id="_60">Treatment of tumors of the paranasal sinuses and of the nasal cavity should be
planned on an individual basis because of the complexity involved.
</Para></SummarySection><ReferenceSection><Citation idx="1">Mendenhall WM, Werning JW, Pfister DG: Treatment of head and neck cancer. In: DeVita VT Jr, Lawrence TS, Rosenberg SA: Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, Pa: Lippincott Williams &amp; Wilkins, 2011, pp 729-80.</Citation><Citation idx="2">Laramore GE, ed.: Radiation Therapy of Head and Neck Cancer. Berlin: Springer-Verlag, 1989.</Citation><Citation idx="3">Thawley SE, Panje WR, Batsakis JG, et al., eds.: Comprehensive Management of Head and Neck Tumors. 2nd ed. Philadelphia, Pa: WB Saunders, 1999.</Citation><Citation idx="4" PMID="1534082" MedlineID="92267912">Fowler JF, Lindstrom MJ: Loss of local control with prolongation in radiotherapy. Int J Radiat Oncol Biol Phys 23 (2): 457-67, 1992.</Citation><Citation idx="5" PMID="15825201">Ganly I, Patel SG, Singh B, et al.: Craniofacial resection for malignant paranasal sinus tumors: Report of an International Collaborative Study. Head Neck 27 (7): 575-84, 2005.</Citation><Citation idx="6" PMID="7836081" MedlineID="95137798">Turner SL, Tiver KW, Boyages SC: Thyroid dysfunction following radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys 31 (2): 279-83, 1995.</Citation><Citation idx="7" PMID="7836099" MedlineID="95137818">Constine LS: What else don't we know about the late effects of radiation in patients treated for head and neck cancer? Int J Radiat Oncol Biol Phys 31 (2): 427-9, 1995.</Citation><Citation idx="8" PMID="1732427" MedlineID="92121936">Jacobs C, Lyman G, Velez-García E, et al.: A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 10 (2): 257-63, 1992.</Citation><Citation idx="9" PMID="7602354" MedlineID="95325882">Schornagel JH, Verweij J, de Mulder PH, et al.: Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study. J Clin Oncol 13 (7): 1649-55, 1995.</Citation></ReferenceSection></SummarySection><SummarySection id="_62"><SectMetaData><SpecificDiagnosis ref="CDR0000040128">stage I paranasal sinus and nasal cavity cancer</SpecificDiagnosis><SectionType>Treatment options by stage</SectionType></SectMetaData><Title>Stage I Paranasal Sinus and Nasal Cavity Cancer</Title><Para id="_224">Stage I  disease includes small lesions.</Para><Para id="_64"><Strong>Standard treatment options:</Strong>
</Para><OrderedList id="_193" Style="Arabic" Compact="No"><ListItem>For maxillary sinus tumors (small lesions of the infrastructure):
<ItemizedList id="_66" Style="bullet"><ListItem>Surgical resection.
</ListItem>
<ListItem>Postoperative radiation therapy should be considered for close margins
(particularly in tumors of the suprastructure).

</ListItem>
</ItemizedList></ListItem><ListItem>For ethmoid sinus tumors (lesions are usually extensive when diagnosed):<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/>

<ItemizedList id="_70" Style="bullet"><ListItem>Generally, external-beam radiation therapy alone is used for
unresectable lesions.

</ListItem>
<ListItem>Well-localized lesions can be resected, but it generally requires
resection of the ethmoids, maxilla, and orbit with consideration for
a craniofacial approach.

</ListItem>
<ListItem>If surgery can be done with good functional and cosmetic results,
postoperative radiation therapy should be given even with clear
surgical margins.

</ListItem>
</ItemizedList></ListItem><ListItem>For sphenoid sinus tumors:<ItemizedList id="_75" Style="bullet"><ListItem>Treatment is the same as for nasopharyngeal cancers, primarily
radiation therapy. (Refer to the <SummaryRef href="CDR0000062918#_54" url="/types/head-and-neck/hp/nasopharyngeal-treatment-pdq">Stage I Nasopharyngeal Cancer</SummaryRef> section in the PDQ summary on <SummaryRef href="CDR0000062918" url="/types/head-and-neck/hp/nasopharyngeal-treatment-pdq">Nasopharyngeal Cancer Treatment</SummaryRef> for more information.)</ListItem>

</ItemizedList></ListItem><ListItem>For nasal cavity tumors (squamous cell carcinomas), treatment preferences
are either surgery or radiation therapy with equal cure rates:
<ItemizedList id="_77" Style="bullet"><ListItem>Surgery for tumors of the septum.
</ListItem>
<ListItem>Radiation therapy for tumors of the lateral and superior walls.<Reference refidx="4"/>
</ListItem>
<ListItem>Surgery plus radiation therapy for tumors of the septal and lateral
walls.<Reference refidx="5"/></ListItem>

</ItemizedList></ListItem><ListItem>For inverting papilloma:
<ItemizedList id="_79" Style="bullet"><ListItem>Surgical excision.
</ListItem>
<ListItem>Re-excision for surgery failures.
</ListItem>
<ListItem>Radical surgery may eventually be necessary.
</ListItem>
<ListItem>Radiation has been used successfully for surgical failures.
</ListItem>
</ItemizedList></ListItem><ListItem> For melanomas and sarcomas:
<ItemizedList id="_81" Style="bullet"><ListItem>Surgical excision if possible.
</ListItem>
<ListItem>Combined surgery, radiation, and chemotherapy are recommended for
rhabdomyosarcoma.
</ListItem>
</ItemizedList></ListItem><ListItem> For midline granuloma:<ItemizedList id="_84" Style="bullet"><ListItem>Radiation therapy to nasal cavity and paranasal sinuses.
</ListItem>
</ItemizedList></ListItem><ListItem>For nasal vestibule tumors:<ItemizedList id="_86" Style="bullet"><ListItem> Surgery or radiation may be performed.  If lesions are extremely small,
surgery is preferred provided that no deformity is expected and a need
for reconstruction is not anticipated.  Radiation therapy is preferred
for other small lesions.<Reference refidx="6"/><Reference refidx="7"/>  Treatment of the ipsilateral neck should be considered.
</ListItem>




</ItemizedList></ListItem></OrderedList><SummarySection id="_TrialSearch_62_sid_5"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_62_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=40128&amp;tt=1&amp;format=2&amp;cn=1">stage I paranasal sinus and nasal cavity cancer</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_62_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="1313248" MedlineID="92207473">Kraus DH, Sterman BM, Levine HL, et al.: Factors influencing survival in ethmoid sinus cancer. Arch Otolaryngol Head Neck Surg 118 (4): 367-72, 1992.</Citation><Citation idx="2" PMID="10635391" MedlineID="20101308">Shah JP: Surgery of the anterior skull base for malignant tumors. Acta Otorhinolaryngol Belg 53 (3): 191-4, 1999.</Citation><Citation idx="3" PMID="10208659" MedlineID="99223358">Cantù G, Solero CL, Mariani L, et al.: Anterior craniofacial resection for malignant ethmoid tumors--a series of 91 patients. Head Neck 21 (3): 185-91, 1999.</Citation><Citation idx="4" PMID="2846481" MedlineID="89033230">Hawkins RB, Wynstra JH, Pilepich MV, et al.: Carcinoma of the nasal cavity--results of primary and adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 15 (5): 1129-33, 1988.</Citation><Citation idx="5" PMID="1410570" MedlineID="93029625">Ang KK, Jiang GL, Frankenthaler RA, et al.: Carcinomas of the nasal cavity. Radiother Oncol 24 (3): 163-8, 1992.</Citation><Citation idx="6" PMID="2262359" MedlineID="91086145">Levendag PC, Pomp J: Radiation therapy of squamous cell carcinoma of the nasal vestibule. Int J Radiat Oncol Biol Phys 19 (6): 1363-7, 1990.</Citation><Citation idx="7" PMID="3046644" MedlineID="88326701">Wong CS, Cummings BJ: The place of radiation therapy in the treatment of squamous cell carcinoma of the nasal vestibule. A review. Acta Oncol 27 (3): 203-8, 1988.</Citation></ReferenceSection></SummarySection><SummarySection id="_87"><SectMetaData><SpecificDiagnosis ref="CDR0000040129">stage II paranasal sinus and nasal cavity cancer</SpecificDiagnosis><SectionType>Treatment options by stage</SectionType></SectMetaData><Title>Stage II Paranasal Sinus and Nasal Cavity Cancer</Title><Para id="_225">Stage II disease includes small and moderately advanced lesions.</Para><Para id="_89"><Strong>Standard treatment options:
</Strong></Para><OrderedList id="_194" Style="Arabic" Compact="No"><ListItem>For maxillary sinus tumors:
<ItemizedList id="_91" Style="bullet"><ListItem>Surgical resection with high-dose preoperative or postoperative
radiation therapy.</ListItem>

</ItemizedList></ListItem><ListItem>For ethmoid sinus tumors (lesions are usually extensive when diagnosed):<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/>
<ItemizedList id="_94" Style="bullet"><ListItem>Generally, external-beam radiation therapy alone is used and produces
better overall results than surgery.

</ListItem>
<ListItem>Well-localized lesions can be resected, but resection of the ethmoids,
maxilla, and orbit, often with a combined neurosurgical sinus
craniofacial approach, is generally required.

</ListItem>
<ListItem>If surgery can be done with good functional and cosmetic results,
postoperative radiation therapy should be given even with clear
surgical margins.

</ListItem>
</ItemizedList></ListItem><ListItem> For sphenoid sinus tumors:<ItemizedList id="_99" Style="bullet"><ListItem>Treatment is the same as for nasopharyngeal cancers, primarily
radiation therapy. (Refer to the <SummaryRef href="CDR0000062918#_57" url="/types/head-and-neck/hp/nasopharyngeal-treatment-pdq">Stage II Nasopharyngeal Cancer</SummaryRef> section in the PDQ summary on <SummaryRef href="CDR0000062918" url="/types/head-and-neck/hp/nasopharyngeal-treatment-pdq">Nasopharyngeal Cancer Treatment</SummaryRef> for more information.)  Concomitant chemotherapy and radiation therapy may be considered.</ListItem>

</ItemizedList></ListItem><ListItem>For nasal cavity tumors (squamous cell carcinomas), treatment preferences
are either surgery or radiation therapy, which have equal cure rates:<Reference refidx="4"/><ItemizedList id="_101" Style="bullet"><ListItem>Surgery or radiation therapy for tumors of the septum.
</ListItem>
<ListItem>Radiation therapy for tumors of the lateral and superior walls.
Concomitant chemotherapy and radiation therapy may be considered.</ListItem>
<ListItem>Surgery plus radiation therapy for tumors of the septal and lateral
walls.<Reference refidx="5"/></ListItem>

</ItemizedList></ListItem><ListItem>For inverting papilloma:
<ItemizedList id="_103" Style="bullet"><ListItem>Surgical excision.
</ListItem>
<ListItem>Re-excision for surgery failures.
</ListItem>
<ListItem>Radiation therapy for radical surgery failures may eventually be
necessary.

</ListItem>
</ItemizedList></ListItem><ListItem> For melanomas and sarcomas:
<ItemizedList id="_106" Style="bullet"><ListItem>Surgical excision if possible.
</ListItem>
<ListItem>Combined surgery, radiation, and chemotherapy are recommended for
rhabdomyosarcoma.

</ListItem>
</ItemizedList></ListItem><ListItem>For midline granuloma:
<ItemizedList id="_109" Style="bullet"><ListItem>Radiation therapy to nasal cavity and paranasal sinuses.
</ListItem>
</ItemizedList></ListItem><ListItem>For nasal vestibule tumors:
<ItemizedList id="_111" Style="bullet"><ListItem>Surgery or radiation therapy may be performed.  If tumors are extremely
small, surgery is preferred provided that no deformity is expected and
a need for reconstruction is not anticipated.  Radiation therapy is
preferred for other small lesions.<Reference refidx="6"/><Reference refidx="7"/>  Treatment of the neck should
be considered.
</ListItem>




</ItemizedList></ListItem></OrderedList><SummarySection id="_TrialSearch_87_sid_6"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_87_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=40129&amp;tt=1&amp;format=2&amp;cn=1">stage II paranasal sinus and nasal cavity cancer</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_87_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="1313248" MedlineID="92207473">Kraus DH, Sterman BM, Levine HL, et al.: Factors influencing survival in ethmoid sinus cancer. Arch Otolaryngol Head Neck Surg 118 (4): 367-72, 1992.</Citation><Citation idx="2" PMID="10208659" MedlineID="99223358">Cantù G, Solero CL, Mariani L, et al.: Anterior craniofacial resection for malignant ethmoid tumors--a series of 91 patients. Head Neck 21 (3): 185-91, 1999.</Citation><Citation idx="3" PMID="10635391" MedlineID="20101308">Shah JP: Surgery of the anterior skull base for malignant tumors. Acta Otorhinolaryngol Belg 53 (3): 191-4, 1999.</Citation><Citation idx="4" PMID="2846481" MedlineID="89033230">Hawkins RB, Wynstra JH, Pilepich MV, et al.: Carcinoma of the nasal cavity--results of primary and adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 15 (5): 1129-33, 1988.</Citation><Citation idx="5" PMID="1410570" MedlineID="93029625">Ang KK, Jiang GL, Frankenthaler RA, et al.: Carcinomas of the nasal cavity. Radiother Oncol 24 (3): 163-8, 1992.</Citation><Citation idx="6" PMID="2262359" MedlineID="91086145">Levendag PC, Pomp J: Radiation therapy of squamous cell carcinoma of the nasal vestibule. Int J Radiat Oncol Biol Phys 19 (6): 1363-7, 1990.</Citation><Citation idx="7" PMID="3046644" MedlineID="88326701">Wong CS, Cummings BJ: The place of radiation therapy in the treatment of squamous cell carcinoma of the nasal vestibule. A review. Acta Oncol 27 (3): 203-8, 1988.</Citation></ReferenceSection></SummarySection><SummarySection id="_112"><SectMetaData><SpecificDiagnosis ref="CDR0000040130">stage III paranasal sinus and nasal cavity cancer</SpecificDiagnosis><SectionType>Treatment options by stage</SectionType></SectMetaData><Title>Stage III Paranasal Sinus and Nasal Cavity Cancer</Title><Para id="_226">Stage III disease includes small and moderately advanced lesions.</Para><Para id="_114"><Strong>Standard treatment options:</Strong>
</Para><OrderedList id="_195" Style="Arabic" Compact="No"><ListItem>For maxillary sinus tumors:
<ItemizedList id="_116" Style="bullet"><ListItem>Surgical resection with high-dose preoperative or postoperative
radiation therapy.
</ListItem>
</ItemizedList></ListItem><ListItem>For ethmoid sinus tumors:<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/><ItemizedList id="_119" Style="bullet"><ListItem>Generally a craniofacial resection in combination with postoperative
radiation therapy.
</ListItem>
</ItemizedList></ListItem><ListItem>For sphenoid sinus tumors:
<ItemizedList id="_122" Style="bullet"><ListItem>Treatment is the same as for nasopharyngeal cancers, primarily
radiation therapy.
(Refer to the <SummaryRef href="CDR0000062918#_61" url="/types/head-and-neck/hp/nasopharyngeal-treatment-pdq">Stage III Nasopharyngeal Cancer</SummaryRef> section in the PDQ summary on <SummaryRef href="CDR0000062918" url="/types/head-and-neck/hp/nasopharyngeal-treatment-pdq">Nasopharyngeal Cancer Treatment</SummaryRef> for more information.) </ListItem>

<ListItem>Concomitant chemotherapy and radiation therapy may be considered.</ListItem></ItemizedList></ListItem><ListItem> For nasal cavity tumors (squamous cell carcinomas [SCC]):
<ItemizedList id="_124" Style="bullet"><ListItem>Surgery alone.
</ListItem>
<ListItem>Radiation therapy alone.<Reference refidx="4"/> Concomitant chemotherapy and radiation therapy may be considered.
</ListItem>
<ListItem>Combined surgery and radiation therapy (postoperative radiation
therapy is preferred).<Reference refidx="4"/><Reference refidx="5"/>
</ListItem>
</ItemizedList></ListItem><ListItem>For inverting papilloma:
<ItemizedList id="_127" Style="bullet"><ListItem>Surgical excision.
</ListItem>
<ListItem>Re-excision for surgery failures.
</ListItem>
<ListItem>Radiation therapy or radical surgery may eventually be necessary.</ListItem>
</ItemizedList></ListItem><ListItem> For melanomas and sarcomas:
<ItemizedList id="_129" Style="bullet"><ListItem>Surgical excision if possible, otherwise consider radiation therapy.
</ListItem>
<ListItem>Combined surgery, radiation, and chemotherapy are recommended for
rhabdomyosarcoma.

</ListItem>
</ItemizedList></ListItem><ListItem>For midline granuloma:
<ItemizedList id="_132" Style="bullet"><ListItem>Radiation therapy to nasal cavity and paranasal sinuses.
</ListItem>
</ItemizedList></ListItem><ListItem>For nasal vestibule tumors:
<ItemizedList id="_134" Style="bullet"><ListItem>Generally, radiation is preferred to minimize deformity.<Reference refidx="6"/>  External-beam (photons or electrons) and/or interstitial implantation can be
used.  Surgery is reserved for salvage.
</ListItem>


</ItemizedList></ListItem></OrderedList><Para id="_135"><Strong>Treatment options under clinical evaluation:
</Strong></Para><OrderedList id="_254" Style="Arabic" Compact="No"><ListItem>For maxillary sinus tumors:<ItemizedList id="_255" Style="bullet"><ListItem>Superfractionated preoperative or postoperative radiation therapy.<Reference refidx="7"/></ListItem></ItemizedList></ListItem><ListItem>For ethmoid sinus tumors, nasal cavity tumors (SCC), and
nasal vestibule tumors:<ItemizedList id="_256" Style="bullet"><ListItem>Clinical trials using new drug combinations for advanced tumors should be
considered to evaluate chemotherapy preoperatively or before radiation therapy, or as adjuvant therapy after surgery or after combined modality
therapy.
</ListItem></ItemizedList></ListItem></OrderedList><SummarySection id="_TrialSearch_112_sid_7"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_112_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=40130&amp;tt=1&amp;format=2&amp;cn=1">stage III paranasal sinus and nasal cavity cancer</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_112_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="1313248" MedlineID="92207473">Kraus DH, Sterman BM, Levine HL, et al.: Factors influencing survival in ethmoid sinus cancer. Arch Otolaryngol Head Neck Surg 118 (4): 367-72, 1992.</Citation><Citation idx="2" PMID="10208659" MedlineID="99223358">Cantù G, Solero CL, Mariani L, et al.: Anterior craniofacial resection for malignant ethmoid tumors--a series of 91 patients. Head Neck 21 (3): 185-91, 1999.</Citation><Citation idx="3" PMID="10635391" MedlineID="20101308">Shah JP: Surgery of the anterior skull base for malignant tumors. Acta Otorhinolaryngol Belg 53 (3): 191-4, 1999.</Citation><Citation idx="4" PMID="2846481" MedlineID="89033230">Hawkins RB, Wynstra JH, Pilepich MV, et al.: Carcinoma of the nasal cavity--results of primary and adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 15 (5): 1129-33, 1988.</Citation><Citation idx="5" PMID="1410570" MedlineID="93029625">Ang KK, Jiang GL, Frankenthaler RA, et al.: Carcinomas of the nasal cavity. Radiother Oncol 24 (3): 163-8, 1992.</Citation><Citation idx="6" PMID="3046644" MedlineID="88326701">Wong CS, Cummings BJ: The place of radiation therapy in the treatment of squamous cell carcinoma of the nasal vestibule. A review. Acta Oncol 27 (3): 203-8, 1988.</Citation><Citation idx="7" PMID="1571905" MedlineID="92240564">Johnson CR, Schmidt-Ullrich RK, Wazer DE: Concomitant boost technique using accelerated superfractionated radiation therapy for advanced squamous cell carcinoma of the head and neck. Cancer 69 (11): 2749-54, 1992.</Citation></ReferenceSection></SummarySection><SummarySection id="_140"><SectMetaData><SpecificDiagnosis ref="CDR0000040131">stage IV paranasal sinus and nasal cavity cancer</SpecificDiagnosis><SectionType>Treatment options by stage</SectionType></SectMetaData><Title>Stage IV Paranasal Sinus and Nasal Cavity Cancer</Title><Para id="_227">Stage IV disease includes advanced lesions.</Para><Para id="_142"><Strong>Standard treatment options:
</Strong></Para><OrderedList id="_196" Style="Arabic" Compact="No"><ListItem> For maxillary sinus tumors:<ItemizedList id="_228" Style="bullet"><ListItem>High-dose radiation therapy is used because extension to base of skull and nasopharynx is
a potential, but not absolute, contraindication to surgery.  If radiation therapy is to be used alone, localized
drainage of the sinus(es) must be established before initiating radiation
therapy treatments.</ListItem></ItemizedList>
</ListItem><ListItem>For ethmoid sinus tumors:<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/><ItemizedList id="_145" Style="bullet"><ListItem>Generally a craniofacial resection in combination with preoperative or
postoperative radiation therapy.
</ListItem><ListItem>Concomitant chemotherapy and radiation therapy may be considered for patients with inoperable tumors.</ListItem>

</ItemizedList></ListItem><ListItem> For sphenoid sinus tumors:<ItemizedList id="_147" Style="bullet"><ListItem>Treatment is the same as for nasopharyngeal cancers, primarily
radiation therapy.
(Refer to the <SummaryRef href="CDR0000062918#_70" url="/types/head-and-neck/hp/nasopharyngeal-treatment-pdq">Stage IV Nasopharyngeal Cancer</SummaryRef> section in the PDQ summary on <SummaryRef href="CDR0000062918" url="/types/head-and-neck/hp/nasopharyngeal-treatment-pdq">Nasopharyngeal Cancer Treatment</SummaryRef> for more information.)</ListItem><ListItem>Concomitant chemotherapy and radiation therapy may be considered.</ListItem>

</ItemizedList>
</ListItem><ListItem> For nasal cavity tumors (squamous cell carcinomas):
<ItemizedList id="_149" Style="bullet"><ListItem>Surgery alone.
</ListItem>
<ListItem>Radiation alone.<Reference refidx="4"/> Concomitant chemotherapy and radiation therapy may be considered.
</ListItem>
<ListItem>Combined surgery and radiation therapy (postoperative radiation
therapy is preferred).<Reference refidx="4"/>
</ListItem>
</ItemizedList></ListItem><ListItem>For inverting papilloma:
<ItemizedList id="_152" Style="bullet"><ListItem>Surgical excision.
</ListItem>
<ListItem>Re-excision for surgery failures.
</ListItem>
<ListItem>Radiation therapy or radical surgery may eventually be necessary.
</ListItem>
</ItemizedList></ListItem><ListItem> For melanomas and sarcomas:<ItemizedList id="_154" Style="bullet"><ListItem>Surgical excision if possible.
</ListItem>
<ListItem>Appropriate radiation and various chemotherapy agents should be
considered.

</ListItem>
</ItemizedList>
</ListItem><ListItem> For midline granuloma:
<ItemizedList id="_157" Style="bullet"><ListItem>Radiation therapy to nasal cavity and paranasal sinuses.
</ListItem>
</ItemizedList></ListItem><ListItem>For nasal vestibule tumors:
<ItemizedList id="_159" Style="bullet"><ListItem>Generally, radiation is preferred to minimize deformity.  External-beam (i.e., photons or electrons) and/or interstitial implantation can be
used.  Surgery is reserved for salvage.  Treatment of the neck should
be considered.
</ListItem>



</ItemizedList></ListItem></OrderedList><Para id="_160"><Strong>Treatment options under clinical evaluation:
</Strong></Para><OrderedList id="_258" Style="Arabic" Compact="No"><ListItem>For maxillary sinus tumors:<ItemizedList id="_259" Style="bullet"><ListItem>Superfractionated radiation therapy.<Reference refidx="5"/></ListItem></ItemizedList>
</ListItem><ListItem>For maxillary sinus tumors, ethmoid sinus tumors, nasal cavity tumors, and
nasal vestibule tumors:<ItemizedList id="_260" Style="bullet"><ListItem>Clinical trials for advanced tumors should be
considered to evaluate chemotherapy preoperatively or before radiation therapy,
as is adjuvant therapy after surgery or after combined modality therapy.</ListItem><ListItem>Concomitant chemotherapy and radiation therapy may be considered.</ListItem></ItemizedList></ListItem></OrderedList><Para id="_261">Neoadjuvant chemotherapy as employed in clinical trials has been used to shrink
tumors and to render them more definitively treatable with either surgery
or radiation.  This chemotherapy is given prior to the other modalities; therefore, 
the designation of neoadjuvant is used to distinguish it from standard adjuvant therapy,
which is given after or during definitive therapy with radiation or after
surgery.  Many drug combinations have been used in  neoadjuvant
chemotherapy.<Reference refidx="6"/><Reference refidx="7"/><Reference refidx="8"/></Para><SummarySection id="_TrialSearch_140_sid_8"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_140_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=40131&amp;tt=1&amp;format=2&amp;cn=1">stage IV paranasal sinus and nasal cavity cancer</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_140_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="1313248" MedlineID="92207473">Kraus DH, Sterman BM, Levine HL, et al.: Factors influencing survival in ethmoid sinus cancer. Arch Otolaryngol Head Neck Surg 118 (4): 367-72, 1992.</Citation><Citation idx="2" PMID="10208659" MedlineID="99223358">Cantù G, Solero CL, Mariani L, et al.: Anterior craniofacial resection for malignant ethmoid tumors--a series of 91 patients. Head Neck 21 (3): 185-91, 1999.</Citation><Citation idx="3" PMID="10635391" MedlineID="20101308">Shah JP: Surgery of the anterior skull base for malignant tumors. Acta Otorhinolaryngol Belg 53 (3): 191-4, 1999.</Citation><Citation idx="4" PMID="2846481" MedlineID="89033230">Hawkins RB, Wynstra JH, Pilepich MV, et al.: Carcinoma of the nasal cavity--results of primary and adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 15 (5): 1129-33, 1988.</Citation><Citation idx="5" PMID="1571905" MedlineID="92240564">Johnson CR, Schmidt-Ullrich RK, Wazer DE: Concomitant boost technique using accelerated superfractionated radiation therapy for advanced squamous cell carcinoma of the head and neck. Cancer 69 (11): 2749-54, 1992.</Citation><Citation idx="6" PMID="8209266" MedlineID="94269651">Stupp R, Weichselbaum RR, Vokes EE: Combined modality therapy of head and neck cancer. Semin Oncol 21 (3): 349-58, 1994.</Citation><Citation idx="7" PMID="3278391" MedlineID="88145720">Al-Sarraf M: Head and neck cancer: chemotherapy concepts. Semin Oncol 15 (1): 70-85, 1988.</Citation><Citation idx="8" PMID="8418313" MedlineID="93116111">Dimery IW, Hong WK: Overview of combined modality therapies for head and neck cancer. J Natl Cancer Inst 85 (2): 95-111, 1993.</Citation></ReferenceSection></SummarySection><SummarySection id="_165"><SectMetaData><SpecificDiagnosis ref="CDR0000040132">recurrent paranasal sinus and nasal cavity cancer</SpecificDiagnosis><SectionType>Treatment options for recurrent cancer</SectionType></SectMetaData><Title>Recurrent Paranasal Sinus and Nasal Cavity Cancer</Title><Para id="_166">Chemotherapy for recurrent head and neck squamous cell cancer has shown
promise.  Chemotherapy may be indicated where there is recurrence in either
distant or local disease after primary surgery or radiation, and when there is
residual disease after primary treatment.<Reference refidx="1"/><Reference refidx="2"/>  Survival may be improved in
those achieving a complete response to chemotherapy.<Reference refidx="3"/>  Combined modality
therapy with platinum and radiation therapy has been used in trials such as  UMCC-8810.<Reference refidx="4"/>  
</Para><Para id="_167"><Strong>Standard treatment options:
</Strong></Para><OrderedList id="_198" Style="Arabic" Compact="No"><ListItem>For maxillary sinus tumors:
<ItemizedList id="_169" Style="bullet"><ListItem>After surgery, radiation therapy or craniofacial resection with
postoperative radiation therapy.

</ListItem>
<ListItem>After radiation therapy, craniofacial resection if indicated.
</ListItem>
<ListItem>Chemotherapy should be considered after failure of the above.
</ListItem>
</ItemizedList></ListItem><ListItem> For ethmoid sinus tumors:<Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/><ItemizedList id="_172" Style="bullet"><ListItem>After limited surgery, craniofacial resection or radiation therapy or
both.

</ListItem>
<ListItem>After radiation therapy, craniofacial resection.
</ListItem>
<ListItem>Chemotherapy should be considered after failure of the above.
</ListItem>
</ItemizedList></ListItem><ListItem>For sphenoid sinus tumors:<ItemizedList id="_175" Style="bullet"><ListItem>Treatment is the same as for nasopharyngeal cancers, primarily
radiation therapy.

</ListItem>
<ListItem>Chemotherapy should be considered after failure of the above.
</ListItem>
</ItemizedList>
</ListItem><ListItem> For nasal cavity tumors (squamous cell carcinomas) salvage is possible in
approximately 25% of patients:
<ItemizedList id="_178" Style="bullet"><ListItem>For failure after radiation therapy, craniofacial resection.
</ListItem>
<ListItem>For failure after surgery, radiation therapy.
</ListItem>
<ListItem>Chemotherapy should be considered after failure of the above.
</ListItem>
</ItemizedList></ListItem><ListItem>For inverting papilloma:
<ItemizedList id="_180" Style="bullet"><ListItem>Surgical excision.
</ListItem>
<ListItem>Re-excision for surgery failures.
</ListItem>
<ListItem>Radical surgery or radiation therapy may eventually be necessary.
</ListItem>
</ItemizedList></ListItem><ListItem>For melanomas and sarcomas:
<ItemizedList id="_182" Style="bullet"><ListItem>Surgical excision if possible.
</ListItem>
<ListItem>Appropriate chemotherapy geared specifically to cell type. (Refer to the <SummaryRef href="CDR0000062918#_80" url="/types/head-and-neck/hp/nasopharyngeal-treatment-pdq">Recurrent Nasopharyngeal Cancer</SummaryRef> section and the <SummaryRef href="CDR0000062920#_96" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">Recurrent Major Salivary Gland Cancer</SummaryRef> section of the PDQ summaries on <SummaryRef href="CDR0000062918" url="/types/head-and-neck/hp/nasopharyngeal-treatment-pdq">Nasopharyngeal Cancer Treatment</SummaryRef>  and <SummaryRef href="CDR0000062920" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">Salivary Gland Cancer Treatment</SummaryRef>, respectively,  for more information.)</ListItem>
</ItemizedList></ListItem><ListItem>For midline granuloma:
<ItemizedList id="_185" Style="bullet"><ListItem>Radiation therapy to nasal cavity and paranasal sinuses.
</ListItem>
</ItemizedList></ListItem><ListItem>For nasal vestibule tumors:
<ItemizedList id="_187" Style="bullet"><ListItem>For radiation therapy failures, surgery.
</ListItem>
<ListItem>For surgery failures, radiation therapy or a combination of surgery and
radiation therapy.
</ListItem>
<ListItem>Chemotherapy should be considered after failure of the above.
</ListItem>
</ItemizedList></ListItem></OrderedList><Para id="_189"><Strong>Treatment options under clinical evaluation:
</Strong></Para><ItemizedList id="_199" Style="bullet"><ListItem>For maxillary sinus tumors, ethmoid sinus tumors, nasal cavity tumors, and
nasal vestibule tumors, clinical trials using chemotherapy should be
considered.<Reference refidx="8"/><Reference refidx="9"/>
</ListItem></ItemizedList><SummarySection id="_TrialSearch_165_sid_9"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_165_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=40132&amp;tt=1&amp;format=2&amp;cn=1">recurrent paranasal sinus and nasal cavity cancer</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_165_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="4047673" MedlineID="86015609">Kies MS, Levitan N, Hong WK: Chemotherapy of head and neck cancer. Otolaryngol Clin North Am 18 (3): 533-41, 1985.</Citation><Citation idx="2" PMID="2454717" MedlineID="88253092">LoRusso P, Tapazoglou E, Kish JA, et al.: Chemotherapy for paranasal sinus carcinoma. A 10-year experience at Wayne State University. Cancer 62 (1): 1-5, 1988.</Citation><Citation idx="3" PMID="2433016" MedlineID="87102455">Al-Kourainy K, Kish J, Ensley J, et al.: Achievement of superior survival for histologically negative versus histologically positive clinically complete responders to cisplatin combination in patients with locally advanced head and neck cancer. Cancer 59 (2): 233-8, 1987.</Citation><Citation idx="4" PMID="3802013" MedlineID="87102459">Al-Sarraf M, Pajak TF, Marcial VA, et al.: Concurrent radiotherapy and chemotherapy with cisplatin in inoperable squamous cell carcinoma of the head and neck. An RTOG Study. Cancer 59 (2): 259-65, 1987.</Citation><Citation idx="5" PMID="1313248" MedlineID="92207473">Kraus DH, Sterman BM, Levine HL, et al.: Factors influencing survival in ethmoid sinus cancer. Arch Otolaryngol Head Neck Surg 118 (4): 367-72, 1992.</Citation><Citation idx="6" PMID="10208659" MedlineID="99223358">Cantù G, Solero CL, Mariani L, et al.: Anterior craniofacial resection for malignant ethmoid tumors--a series of 91 patients. Head Neck 21 (3): 185-91, 1999.</Citation><Citation idx="7" PMID="10635391" MedlineID="20101308">Shah JP: Surgery of the anterior skull base for malignant tumors. Acta Otorhinolaryngol Belg 53 (3): 191-4, 1999.</Citation><Citation idx="8" PMID="8663951">Brasnu D, Laccourreye O, Bassot V, et al.: Cisplatin-based neoadjuvant chemotherapy and combined resection for ethmoid sinus adenocarcinoma reaching and/or invading the skull base. Arch Otolaryngol Head Neck Surg 122 (7): 765-8, 1996.</Citation><Citation idx="9" PMID="12598339">Licitra L, Locati LD, Cavina R, et al.: Primary chemotherapy followed by anterior craniofacial resection and radiotherapy for paranasal cancer. Ann Oncol 14 (3): 367-72, 2003.</Citation></ReferenceSection></SummarySection><SummarySection id="_206"><SectMetaData><SectionType>Changes to summary</SectionType></SectMetaData><Title>Changes to This Summary (04/21/2015)</Title><Para id="_207">The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available.  This section describes the latest changes made to this summary as of the date above.</Para><Para id="_318"><Strong><SummaryRef href="CDR0000062931#_54" url="/types/head-and-neck/hp/paranasal-sinus-treatment-pdq">Treatment Option Overview</SummaryRef></Strong></Para><Para id="_319">Editorial changes were made to this section.</Para><Para id="_disclaimerHP_3">This summary is written and maintained by the <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq/adult-treatment-board">PDQ Adult Treatment Editorial Board</ExternalRef>, which is
editorially independent of NCI.  The summary reflects an independent review of
the literature and does not represent a policy statement of NCI or NIH.  More
information about summary policies and the role of the PDQ Editorial Boards  in
maintaining the PDQ summaries can be found on the <SummaryRef href="CDR0000062931#_AboutThis_1" url="http://www.cancer.gov/types/head-and-neck/hp/paranasal-sinus-treatment-pdq">About This PDQ Summary</SummaryRef> and <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq">PDQ NCI's Comprehensive Cancer Database</ExternalRef> pages.
</Para></SummarySection><SummarySection id="_AboutThis_1"><Title>About This PDQ Summary</Title><SummarySection id="_AboutThis_2"><Title>Purpose of This Summary</Title><Para id="_AboutThis_3">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of paranasal sinus and nasal cavity cancer. It is intended as a resource to inform and assist clinicians who care for cancer patients.  It does not provide formal guidelines or recommendations for making health care decisions.</Para></SummarySection><SummarySection id="_AboutThis_4"><Title>Reviewers and Updates</Title><Para id="_AboutThis_5">This summary is reviewed regularly and updated as necessary by the <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq/adult-treatment-board">PDQ Adult Treatment Editorial Board</ExternalRef>, which is editorially independent of the National Cancer Institute (NCI).  The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</Para><Para id="_AboutThis_22"> Board members review recently published articles each month to determine whether an article should:</Para><ItemizedList id="_AboutThis_6" Style="bullet"><ListItem>be discussed at a meeting,</ListItem><ListItem>be cited with text, or</ListItem><ListItem>replace or update an existing article that is already cited.</ListItem></ItemizedList><Para id="_AboutThis_7">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in  the published articles and determine how the article should be included in the summary.</Para><Para>The lead reviewers for Paranasal Sinus and Nasal Cavity Cancer Treatment are:</Para><ItemizedList Style="bullet"><ListItem>Scharukh Jalisi, MD, FACS (Boston University Medical Center)</ListItem><ListItem>Eva Szabo, MD (National Cancer Institute)</ListItem><ListItem>Minh Tam Truong, MD (Boston University Medical Center)</ListItem></ItemizedList><Para id="_AboutThis_9">Any comments or questions about the summary content should be submitted to Cancer.gov through the Web site's <ExternalRef xref="http://www.cancer.gov/contact">Contact Form</ExternalRef>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</Para></SummarySection><SummarySection id="_AboutThis_10"><Title>Levels of Evidence</Title><Para id="_AboutThis_11">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Adult Treatment Editorial Board uses a <SummaryRef href="CDR0000062796" url="/publications/pdq/levels-evidence/treatment">formal evidence ranking system</SummaryRef> in developing its level-of-evidence designations.</Para></SummarySection><SummarySection id="_AboutThis_12"><Title>Permission to Use This Summary</Title><Para id="_AboutThis_13">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”</Para><Para id="_AboutThis_14">The preferred citation for this PDQ summary is:</Para><Para id="_AboutThis_15">National Cancer Institute: PDQ® Paranasal Sinus and Nasal Cavity Cancer Treatment. Bethesda, MD: National Cancer Institute. Date last modified  &lt;MM/DD/YYYY&gt;. Available at: <ExternalRef xref="http://www.cancer.gov/types/head-and-neck/hp/paranasal-sinus-treatment-pdq">http://www.cancer.gov/types/head-and-neck/hp/paranasal-sinus-treatment-pdq</ExternalRef>.  Accessed &lt;MM/DD/YYYY&gt;.</Para><Para id="_AboutThis_16">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by  the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <ExternalRef xref="http://visualsonline.cancer.gov/">Visuals Online</ExternalRef>, a collection of over 2,000 scientific images.

</Para></SummarySection><SummarySection id="_AboutThis_17"><Title>Disclaimer</Title><Para id="_AboutThis_18">Based on the strength of the available evidence, treatment options may be described as either “standard” or “under clinical evaluation.” These classifications should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <ExternalRef xref="http://www.cancer.gov/cancertopics/coping/financial-legal">Coping with Cancer: Financial, Insurance, and Legal Information</ExternalRef> page.</Para></SummarySection><SummarySection id="_AboutThis_20"><Title>Contact Us</Title><Para id="_AboutThis_21">More information about contacting us or receiving help with the Cancer.gov Web site can be found on our <ExternalRef xref="http://www.cancer.gov/help">Contact Us for Help</ExternalRef> page. Questions can also be submitted to Cancer.gov through the Web site’s <ExternalRef xref="http://www.cancer.gov/contact">Contact Form</ExternalRef>.
</Para></SummarySection></SummarySection> 

  <SummarySection id="_GetMore_3"><Title>Get More Information From NCI</Title><Para id="_GetMore_15"><Emphasis><Strong>Call 1-800-4-CANCER</Strong></Emphasis></Para><Para id="_GetMore_16">For more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time.  A trained Cancer Information Specialist is available to answer your questions.</Para><Para id="_GetMore_25"><Emphasis><Strong>Chat online 
</Strong></Emphasis></Para><Para id="_GetMore_26">The <ExternalRef xref="https://livehelp.cancer.gov/">NCI's LiveHelp®</ExternalRef> online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer.
</Para><Para id="_GetMore_27"><Emphasis><Strong>Write to us</Strong></Emphasis></Para><Para id="_GetMore_28">For more information from the NCI, please write to this address:</Para><ItemizedList id="_GetMore_29" Style="simple"><ListItem>NCI Public Inquiries Office</ListItem><ListItem>9609 Medical Center Dr. </ListItem><ListItem>Room 2E532 MSC 9760</ListItem><ListItem>Bethesda, MD 20892-9760</ListItem></ItemizedList><Para id="_GetMore_17"><Emphasis><Strong>Search the NCI Web site</Strong></Emphasis></Para><Para id="_GetMore_18">The <ExternalRef xref="http://cancer.gov">NCI Web site</ExternalRef> provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support and resources for cancer patients and their families.  For a quick search, use the search box in the upper right corner of each Web page. The results for a wide range of search terms will include a list of "Best Bets," editorially chosen Web pages that are most closely related to the search term entered.</Para><Para id="_GetMore_30">There are also many other places to get materials and information about cancer treatment and services.      Hospitals in your area may have information about  local and regional agencies that have information on finances, getting to and from treatment, receiving care at home, and dealing with problems related to cancer treatment.</Para><Para id="_GetMore_19"><Emphasis><Strong>Find Publications</Strong></Emphasis></Para><Para id="_GetMore_20">The NCI has booklets and other materials for patients, health professionals, and the public.  These publications discuss types of cancer, methods of cancer treatment, coping with cancer, and clinical trials.  Some publications provide information on tests for cancer, cancer causes and prevention, cancer statistics, and NCI research activities.  NCI materials on these and other topics may be ordered online or printed directly from the <ExternalRef xref="https://pubs.cancer.gov/ncipl">NCI Publications Locator</ExternalRef>. These materials can also be ordered by telephone from the Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237).</Para></SummarySection><DateLastModified>2015-04-21</DateLastModified></Summary>
